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Abstract  
Objective Micro (mi)RNA, small non-coding RNA fragments involved in gene regulation, and 
microvesicles (MV), membrane-bound particles <1μm known to regulate cellular processes including 
responses to injury, may serve as disease specific biomarkers of acute kidney injury (AKI). We 
evaluated the feasibility of measuring these signals as well as other known AKI biomarkers in a mixed 
paediatric cardiac surgery population. 
Design: Single centre prospective cohort feasibility study. 
Setting: Paediatric Intensive Care Unit 
Patients Twenty four children (≤17yrs), undergoing cardiac surgery with cardiopulmonary bypass 
(CPB) without pre-existing inflammatory state, AKI, or extracorporeal life support.  
Interventions: None 
Measurements and Main Results: AKI was defined according to modified KDIGO criteria. Blood and 
urine samples were collected pre-operatively and at 6-12 and 24 hours. MV derivation was assessed 
using flow cytometry and NanoSight analysis. miRNAs were isolated from plasma and analysed by 
microarray and quantitative real time polymerase chain reaction. Data completeness for the primary 
outcomes was 100%. Patients with AKI (n=14/24) were younger, underwent longer CPB, and 
required greater inotrope support. AKI subjects had different fractional content of platelets and 
endothelial-derived MV before surgery. Platelets and endothelial MV levels were higher in AKI 
patients. A number of miRNA species were differentially expressed in AKI patients. Pathway analysis 
of candidate target genes in the kidney suggested that the most often affected pathways were 
phosphatase and tensin homolog (PTEN) and signal transducer and activator of transcription 3 
(STAT3) signalling. 
Conclusions Microvesicles and miRNAs expression patterns in paediatric cardiac surgery patients can 
be measured in children and potentially serve as tools for stratification of patients at risk of AKI.  
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Introduction 
Acute kidney injury (AKI) occurs in 30% to 50% of paediatric cardiac surgery patients where it 
is associated with increased mortality, morbidity and the use of healthcare resources1-3 Improving 
outcomes in patients with AKI is a clinical research priority.4 Currently, our understanding of the 
underlying pathogenesis is poor and there are no effective prevention strategies or treatments 
despite decades of research.5,6 This is particularly evident in the paediatric population where age-
related changes in levels of serum creatinine 7,8 as well as other factors including volume depletion, 
hypotension, and sepsis have significant impact on the diagnosis and contribute to the apparent lack 
of consensus on the definition of AKI in children 9.  As such, serum creatinine does not provide 
sufficient information about the affected tissue, making targeted therapy impossible. Therefore, 
there is a need for new biomarkers that allow earlier and more accurate diagnosis or risk 
stratification in children.10-12   
Plasma derived microvesicles (MV) and micro-RNAs (miRNA) are involved in the regulation of 
cellular processes in health and disease. MV contain cell membrane derived marker proteins from 
the cells they are released from and may serve as cell specific biomarkers of tissue inflammation or 
injury.  Levels of circulating miRNA also correlate well with disease-specific changes in affected 
tissues and their signalling events, which combined with their stability in body fluids, resistance to 
RNases, high pH, temperatures and extended storage, makes them perfect biomarkers.13 These 
characteristics have led to the evaluation of miRNAs’ and MV as biomarkers in a range of diseases. 
For example in cancer patients specific miRNAs have been shown to indicate early recurrence after 
chemotherapy14,15.  
The utility of MV and miRNA as disease specific biomarkers in paediatric cardiac surgery has 
not been well explored and only three miRNAs were selectively tested as AKI biomarkers in a 
previous study 16. The objectives of the current study were: (a) to evaluate the feasibility of 
measuring novel biomarkers (plasma miRNA and MV) of AKI before and after cardiac surgery in a 
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mixed paediatric population.; (b) identify potential AKI pathogenic pathways; (c) evaluate novel 
methods for AKI risk stratification before surgery; and (d) compare the novel biomarkers with 
conventional biomarkers as well as measures of processes thought to be involved in AKI (the 
systemic inflammatory response, and platelet, leucocyte and endothelial activation 17). We 
hypothesized that levels of MV and miRNA will differ in children with and without AKI, reflecting key 
disease processes thought to contribute to post cardiac surgery AKI, and allow stratification of AKI in 
different patient populations.  
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Materials and Methods  
Detailed methods are described in the online only digital Supplement. 
Study design The Microvesicles and miRNA as markers of Acute Kidney Injury following 
paediatric cardiac surgery (pMiVAKI) was a prospective observational cohort feasibility study. The 
study protocol was registered at https://clinicaltrials.gov/ct2/show/NCT02289040, and is included as 
an online appendix. The study was approved by The East Midlands – Nottingham 1 Research Ethics 
Committee. The study is reported as per the STrengthening the Reporting of OBservational studies in 
Epidemiology (STROBE) statement18.  
Study cohort included consecutive patients (defined as newborns if ≤30 days old, infants if 
>30 days and ≤12 months and children if >12 months) who underwent surgery for congenital heart 
diseases at the East Midlands Congenital Heart Centre, Leicester, UK, between October 2014 and 
February 2015. Participants were prospectively recruited if they were younger than 18 years old, 
their body weight was greater than 2 kg and their operation required cardiopulmonary bypass (CPB). 
Patients with pre-existing inflammatory state, sepsis undergoing a treatment or with a chronic 
inflammatory disease or acute kidney injury within 5 days before surgery, emergency or salvage 
procedures and Extracorporeal Membrane Oxygenation (ECMO) were excluded. Written informed 
consent/assent from parents or legal guardians or patients was obtained before enrolment as 
specified in the study protocol.  
Blood sampling Three sets of blood samples (clotting, EDTA, citrate and hirudin) were 
collected from each patient pre-operatively, and 6 – 12 and 24 hours after the end of surgical 
procedure from indwelling arterial lines. Total sample volumes over 24 hr were depended on 
patient’s weight and determined as follows: 2 – 5 kg, 10.8 ml; 5 – 20 kg, 21.6 ml; >20 kg, 28.8 ml.  
Outcomes AKI was determined according to the Kidney Diseases Improving Global 
Outcomes (KDIGO) definition,11 with a modification of the Stage 3 definition to include a reduction in 
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estimated GFR using the Schwartz equation as per the pRIFLE criteria, to adjust for the limited ability 
of small infants to generate high serum creatinine concentrations.19,20 The time frame for the 
assessment of AKI was up to 7 days or hospital discharge if earlier. The primary outcome of the study 
was the feasibility of measuring and comparison between AKI and non AKI patients of the arterial 
plasma MV and miRNA concentrations at baseline, 6-12 and 24 hours following surgery. Outcome 
directly derived from miRNA comparisons between AKI and non AKI groups was identification of 
potential signalling pathways (as listed in Kyoto Encyclopaedia of Genes and Genomes 21) in kidney 
before and after surgery that the miRNA may affect. Secondary outcomes included recruitment and 
dropout rates, protocol adherence defined as the failure to obtain the specified blood volume or 
urine sample required for analysis at the required time, completeness of data, and completeness of 
follow up. As a reference for our proposed novel biomarkers we also measured biomarkers of 
processes considered to have a causal role in post-cardiac surgery AKI including inflammation; urine 
Neutrophil Gelatinase Associated Lipocalcin (NGAL), serum cytokine (IL-6, IL-8, MCP-1, and TNF) 
levels and levels of cell-free haemoglobin, and markers of platelet (P-selectin expression), monocyte 
(CD64 expression) and endothelial activation (soluble ICAM-1). 
Laboratory analysis 
MV analysis was performed in citrated plasma samples spun twice at 1500 xg and stored at -
80˚C. Concentration and size distribution were estimated using NanoSight NS500, nano-particle 
tracking device (Malvern Instruments, Malvern, UK). Derivation of MV was determined with 
fluorescently labelled antibodies against CD-14, CD41, CD144 (all Affymetrix). Samples (20 – 50 μL) 
were labelled with antibodies at 1:20 dilution in PBS for 25 min at RT in total volume 100 μL. The 
samples were analysed by flow cytometry (Cyan ADP, Beckman Coulter). 
miRNA analysis The miRNA was extracted from serum using the miRNeasy kit (Qiagen 
miRNeasy Mini Kit). miRNA samples were combined in 7 pools defined by age and AKI 
(Supplemental Table 1). Total RNA (100ng), from each pool, was reverse transcribed using the 
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TaqMan Multiplex RT set for TaqMan Array Human MicroRNA Panel v2.0 (Applied Biosystems) and 
Veriti thermal cyclers. Pre-amplified cDNA from each pool was analysed using TaqMan® Array 
Human MicroRNA Card A v2.0 (Applied Biosystem).  Quantitative PCR was carried out on an Applied 
BioSystems 7900HT thermocycler. The experiments were performed in triplicates.  
Any assays where cycling time (Ct) value was lower than 20 were removed ΔCt (difference in 
cycling threshold) values were calculated (ΔCt = miRNA Ct—Reference miRNA Ct) using as reference 
control U6 snRNA-001973 present in duplicates on each miRNA array. Undetermined assays were 
assigned zero expression value. Data were normalized across arrays using quantile normalisation.  To 
associate  miRNA, which were significantly different between AKI and non-AKI groups with their 
target genes, lists of miRNA were subjected to Target Filter (Ingenuity Pathway Analysis software 
package, Qiagen) with Tarbase 7.0 and TargetScanHuman. The list of the identified target genes was 
further reduced to those where miRNA regulation was proven experimentally 22 and those where 
potential regulation was predicted with high confidence 23. The list of target genes was further 
filtered for genes encoding proteins in kidney as listed in Human Protein Atlas24,25. The filtered lists 
for before surgery and after surgery in infants and children were subjected to Expression Analysis 
(Ingenuity Pathway Analysis, Qiagen).     
Statistical analysis  
The statistical analysis was performed with SPSS 22.0 (SPSS Inc, Chicago, Ill) and R version 
3.3.2.26 Results were considered statistically significant at the 5% level. All continuous variables were 
tested for normality with the Kolmogorov–Smirnov test and the Shapiro-Wilk test. Non-normally 
distributed variables were log-transformed. Clinical baseline and perioperative outcomes were 
analysed with one-way analysis of variance (ANOVA) and chi-square test. Continuous outcomes 
measured at repeated time points (biomarker concentrations, measures of platelet and leucocyte 
activation) were analysed using linear regression models and analysis of variance (lm and anova – R, 
stats-package), and considered time and age as interaction variables with AKI/ no AKI. Statistical 
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significance of the main and interaction terms was assessed using global F-statistics. In exploratory 
analyses, where p-value < 0.05 the nature of interactions between AKI status, age and time were 
inferred by visual inspection of data plots given the small sample sizes in each subgroup. Clustering 
analysis of miRNA expression profile was performed using hclust program (R, stats package) with 
WardD2 method and distances were calculated using dist program (R, stats package) using Euclidean 
method. Heatmaps of miRNA expression profiles were created using pheamap program (R, 
pheatmap package). In a post hoc analysis Pearson correlations and their significance between 
biomarkers was analysed using cor.test function (R, stats package).   
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Results  
Trial cohort  
Between 26th October 2014 and 7th February 2015, 79 patients were screened of which 71 
were eligible, 46 were approached out of which 14 patients’ surgery was delayed and were not 
asked for consent. Out of 27 consented patients in 2 cases the surgery was cancelled for clinical 
reasons and 1 patient withdrew consent. After withdrawals (STROBE diagram in Supplemental 
Figure 1A) the analysis population comprised 5 newborns, 5 infants and 14 children. Average age for 
newborns was 9 days (range 5.5-13), infants: 242 days (range 147.5-313.5) and for children: 1497 
days (range 1046.5-4949). There were 8 cyanotic patients and 44.2% were females. Details of the 
operations performed are shown in Supplemental Table 2. No deaths or need for ECMO support 
were recorded during the study period. Following cardiac surgery 58.43% of patients developed 
KDIGO defined AKI; 25% (n=6) were classified as stage 1, 12.5% (n=3) as stage 2 and 20.8% (n=5) as 
stage 3. AKI was observed in 5/5 newborns, 3/5 infants and 6/14 children. As expected, serum 
creatinine significantly increased in the AKI group (as indicated by significant AKI, p=2x10-9 and 
AKI*time, p=0.04 terms) and was dependent on patients’ age group as indicated by significant 
interactions with  age (p=0.001 Supplemental Figure 1B and Supplemental Table 4) with highest 
levels in the newborns. AKI patients were more likely to be younger, smaller, and to undergo redo 
procedures or have longer CPB times (Table 1).  Key perioperative characteristics in AKI and non-AKI 
patients are reported in Table 2.  
Protocol compliance Clinical follow up was completed in all patients and assessment of the 
primary outcome was completed in 94.4% of samples. In some patients it was not possible to collect 
blood (n = 4 samples: 1 sample before surgery, 1 sample at 6-12 hr and 2 samples at 24 hr after 
surgery) or urine samples (n = 5 samples: 2 samples before surgery, 1 sample at 6-12 hr and 2 
samples at 24 hr after surgery) because of patient’s discomfort or early removal of indwelling lines 
and urine catheter. No major protocol violations or adverse events related to study procedures were 
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recorded. Sample collection time was adherent to protocol, except for 3 samples. Laboratory and 
data analysis completeness are indicated in Supplemental Figure 1A. 
Primary outcomes 
Microvesicles: There was no overall difference in MV concentrations between AKI and non-
AKI patients (Figure 1A). The MV were of uniform ~180 nm size and there were no significant 
differences in either distribution or concentrations (Figure 1B) between patients who developed AKI 
and those who did not, although a significant interaction was observed between AKI status and 
patients’ age (P value for interaction 0.01).  Exploratory analyses further detected significant 
differences between age groups (p-value = 1.0 x 10-3) and inspection of data plots suggested that MV 
concentrations were higher in children and lower in infants with AKI (Figure 1A, B). Analysis of MV 
derivation using flow cytometry (Figure 1C-E and Supplemental Table 3) identified significantly 
higher levels of platelet derived and endothelial cells derived MV in AKI patients (p-values = 1.49 x 
10-4 and 4.96 x 10-5, respectively). No interaction with time or age group was present. No difference 
was observed for monocyte-derived MV in AKI patients.   
miRNA analysis: Analysis of expression levels indicated that pre-surgery miRNA levels were 
shown to be most different between AKI and non AKI in children and in infants (pre; Figure 2A – B). 
An increase in concentrations at 6-12 hours after surgery was also observed for some miRNA clusters 
(Figure 2A). This was most evident for miRNA expression patterns averaged across samples from all 
patients in samples from both all patients and children only (Figure 2A, first two heatmaps). In 
infants some miRNA clusters showed an opposite pattern where their expression was lower after 
surgery, as compared with other time-points. Strong time dependence was confirmed by clustering 
analysis: Expression patterns at either 6-12 hr or 24 hr time-points clustered together regardless of 
the presence of AKI indicating that surgery has a stronger effect on miRNA expression than the 
presence of AKI (Figure 2B). Again, this was most evident for children expression patterns and when 
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all patients’ data were considered. The clustering analysis also indicated that miRNA expression 
patterns for AKI and non AKI groups were most different before surgery (Figure 2B).   
Differential miRNA expression between AKI and non-AKI groups in samples from patients 
before and after surgery are reported in Table 3. Three miRNAs were found to be significantly 
different in children and infants with AKI (hsa-miR-7g-5p, hsa-miR-152-3p and hsa-miR-320a). 
However while hsa-miR-7g-5p and hsa-miR-152-3p were upregulated in infants with AKI, their 
expression levels were lower in children with AKI as compared with non-AKI patients. For hsa-miR-
320a, an opposite pattern was evident. Target genes of differentially expressed miRNAs were 
identified to explore affected signalling pathways as described in Materials and Methods. The top 
five most likely affected canonical pathways and genes involved in renal toxicity are reported in 
Table 4. The most often affected pathways were PTEN (phosphatase and tensin homolog) and STAT3 
(signal transducer and activator of transcription 3) signalling, particularly after surgery. Most often 
targeted genes before surgery included: VIM, targeted by 5 miRs, and AGO4, ARFIP1, LIN28A, YPEL2, 
ZNF226 each targeted by 4 miRs. Most often targeted genes after surgery included: LCOR, targeted 
by 5 miRs, and AGO4, DDX19B, DICER4, each targeted by 4 miRs.  
Secondary Outcomes 
Urine NGAL was higher in AKI versus non-AKI patients, and this effect did not interact with 
age group (P-value for AKI*age gr. interaction > 0.05; Supplemental Table 4). There were mixed 
changes in serum cytokine markers of the systemic inflammatory response: from IL-8, MCP-1, TNFα 
and IL-6, only the first three were significantly different in patients with and without AKI. For IL-8 a 
significant interaction AKI*time was observed (p-value = 3.0 x 10-3) and its levels were highest 6 hr 
after surgery in AKI patients, overall MCP-1 levels were significantly higher (p-value = 0.04) and TNF 
lower (p-value = 1.82 x 10-4) in AKI patients. TNF also showed significant AKI*age gr interaction (p-
value = 0.01; Supplemental Table 4). Platelets and monocyte activation assessed using flow 
cytometry were significantly higher in AKI patients (p-value = 0.01 for both; Supplemental Table 4). 
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No significant interaction with time was identified for these outcomes, suggesting that these may 
reflect general differences in AKI susceptibility. Levels of cell free haemoglobin where higher in AKI 
patients, with significant interaction between AKI status and age (Supplemental Table 4). Evaluation 
of the plots suggested that cell free haemoglobin was not elevated in neonates with AKI. Serum 
ICAM, a marker of endothelial activation was not different between groups (Supplemental Table 4). 
The majority of markers measured as secondary outcomes did not show any significant correlation 
with any microvesicle variables, except leukocyte activation, which correlated significantly with 
microvesicles derived from platelets (p = 0.02, r = 0.31) and from endothelial cells (p-value = 7.76 x 
10-4). Platelet and endothelial cells-derived microvesicles also significantly correlated with each 
other (p-value = 5.90 x 10-5, r = 0.47). Correlation analysis is shown in Supplemental Table 5.  
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Discussion  
Microvesicles and miRNAs levels are detectable in paediatric cardiac surgery patients of 
every age, including neonates. Exploratory analyses suggest that different age groups have specific 
expression patterns depending on the time after surgery, and AKI status. Analysis of microvesicles 
derivation indicating platelet and endothelial cell activation demonstrated differences between AKI 
and non-AKI groups and along with the results of the analysis of miRNA changes point toward the 
potential utility of these biomarkers for patients’ stratification before surgery. In addition our 
analysis indicated phosphatase and tensin homolog (PTEN) and signal transducer and activator of 
transcription 3 (STAT3) signalling pathways’ potential involvement in AKI pathogenesis in humans.  
Clinical importance 
This study demonstrated the feasibility of miRNA analysis in small blood volumes in 
paediatric population. Our results did not refute the hypothesis that miRNA may serve as 
stratification tools in paediatric patients at risk of developing AKI. We observed overall higher 
concentrations of miRNA after surgery, and miRNA expression heatmaps (Figure 2A) as well as 
clustering analyses (Figure 2B) suggested that certain miRNAs are released specifically in response to 
surgery. Indeed these changes were greater and more consistent than the changes observed in 
miRNA expression between AKI and non AKI groups. This points to the importance of miRNA 
signalling as part of the host response to surgery, as has been reported previously. 16 Different 
expression patterns between children and infants with AKI is also suggestive of age-dependent 
regulation of miRNA release in response to surgery and AKI. Of the differentially expressed miRNAs 
identified in this study hsa-miR-27-3p, hsa-miR-10a-5p,hsa-miR-7g (let-7-5p family), and hsa-miR-
30b-5p (miR-30-5p family) were also identified in two analyses of miRNA AKI biomarkers in adult 
cardiac surgery patients.27,28 In contrast we observed no difference for hsa-miR-210-3p, which was 
reported as an AKI marker in both adult studies.27,28 This may also indicate heterogeneous disease 
processes in adults and children.  
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AKI status had the strongest association with miRNA expression patterns at baseline as 
indicated by the clustering analysis where miRNA expression patterns at pre for AKI and non-AKI 
patients were least similar (different clusters in dendrograms in Figure 2B), suggesting a possible risk 
stratification role for these biomarkers. However, even at baseline, age-dependent miRNA-
expression pattern was evident, particularly for three miRNAs (hsa-let-7g-5p, hsa-miR-152-3p and 
hsa-miR-320a) whose expression was significantly different between AKI and non-AKI groups but 
showed opposite expression patterns in children and infants. This points to the potential utility of 
miRNA analysis to identify different AKI phenotypes, even in different paediatric age groups. To 
verify the clinical utility of these miRNAs a study in a larger cohort of patients is necessary.  Third, 
our findings provide new insights into AKI pathogenesis. Pathway analysis identified PTEN and STAT3 
signalling pathways as affected most often after surgery in AKI patients. Hitherto PTEN has been 
shown to be a key node regulating apoptosis, proliferation and recovery only in rodents.29,30 
Inhibition of PTEN leads to exacerbated renal damage in animal models of AKI triggered by 
ischemia/reperfusion 31,32 or cisplatin 33 as a result of increased levels of apoptosis, immune cell 
infiltration and increased levels of proinflammatory cytokines. Activation STAT3 pathway was also 
shown to have a protective role in AKI since STAT3 deletion leads to more severe ischemia-triggered 
AKI in a mouse model 34. The identified miRNAs targeted PTEN and SMAD3 pathways rather than the 
two proteins, therefore additional research is necessary to determine the role both pathway play in 
AKI. Other miRNA-affected genes included Transforming Growth Factor (TGF)  receptors and SMAD 
(Similar To Mothers Against Decapentaplegic) proteins, which are involved in TGF signalling and 
proliferation. These changes are associated with increased expression of vimentin (targeted by 5 
miRNA identified in this study), which leads to fibrosis.35   
Strengths and limitations 
Although single miRNA were previously measured in paediatric cardiac surgery patients 16 
this is the first study to our knowledge that measured MV and multiple miRNA biomarkers in 
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children who develop AKI after cardiac surgery. There was excellent compliance with the study 
protocol indicating the feasibility of this approach; in total there were 148 laboratory measurements 
for each patient with an overall level of missing laboratory data of 8.1%.  The study used microarrays 
to measure 378 individual miRNAs in pooled samples, with subsequent bioinformatics analysis. Even 
in a small cohort this has provided new information on the molecular processes underlying this 
disease. Platform techniques have seen a rapid reduction in cost over recent years and we suggest 
that the wider application of ‘omics’ to perioperative organ injury will yield important new 
knowledge. Another novel finding was the observation of significant differences between AKI and 
non AKI patients for MV markers of platelet activation that were also evident with direct 
measurement of these processes using flow cytometry. MV analysis in stored samples may therefore 
have the potential to supplant direct measurement of these processes; measures of platelet 
activation typically must be performed within 15 minutes of sample collection which creates 
logistical challenges in clinical studies. In contrast, significant differences in endothelial-derived 
CD144-positive MV did not align with levels of ICAM or CD62E-positive MV. One interpretation is 
that ICAM or CD62E are not good markers of the endothelial injury that underlies AKI in humans36, 
highlighting the value of MV biomarkers in exploring underlying mechanisms. 
The main limitations of the study were the small sample size, and the heterogeneity with respect to 
age, range of heart defects and operations. The study results should therefore be interpreted as 
hypothesis forming rather than definitive. Our analyses did not assess the source of miRNAs, 
whether exosomal or protein bound, limiting our ability to interpret the possible mechanisms 
underlying the observed changes.  MV concentrations measured using the Nanosight showed 
significant variability between patients and this may be considered a further limitation. MV 
derivation was also measured using flow cytometry which is known to have a number of limitations 
for particles smaller than 0.5 μm37 - well above the size of MV observed in the study samples. 
However, flow cytometry remains the primary tool for measurement of MV derivation in clinical 
samples,38,39 we observed very little variability between samples relative to total MV concentrations, 
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and we demonstrated clear differences between groups for MV derivation, supporting this method. 
Another limitation is the observational study design; we are therefore unable to claim that the MV 
or miRNA identified in our analysis have a causal role in AKI pathogenesis, versus parallel or 
consequential processes. We attempted to mitigate this limitation by restricting our bioinformatics 
analysis to protein networks in the kidney. In addition, our MV derivation analyses targeted 
processes that have been previously implicated in trials of off- versus on-pump coronary artery 
bypass surgery as having a causal role in AKI40 and may not reflect processes in paediatric AKI. A final 
limitation is the current consensus definition of paediatric AKI used in the study.10-12 Urinary 
catheters were placed in all patients but were removed within 24 hours in 5 patients, which may 
have introduced bias in AKI detection. However this is unlikely as the removal of urinary catheters 
typically represents a lack of clinical concern about urine output. It is also likely that serum 
creatinine rises denote different processes in neonates versus 16 year old children; indeed 
interaction with age was a common finding for most of the processes studied. In the absence of a 
consensus definition of AKI in neonates at the time the pMIVAKI study was conducted we 
incorporated pRIFLE criteria that use the Schwartz equation for neonates 41. New consensus 
definitions of AKI in neonates have emerged subsequently, however as these remain primarily 
creatinine/ urine output based their clinical utility remains unclear 42.  We suggest that the wider use 
of platform techniques, as performed in this study, to more accurately phenotype AKI will address 
this limitation going forward.  
In summary our results demonstrate the feasibility of measuring multiple MV and miRNA in 
paediatric cardiac surgery patients. These results also point towards a hitherto unreported 
heterogeneity of molecular signals within children suffering from AKI. Our findings support a 
programme of work that will define distinct molecular phenotypes and their underlying processes in 
AKI, and is designed to overcome many of the limitations identified in this feasibility study. We 
suggest that this strategy will lead to the development of novel diagnostic tests, more accurate risk 
stratification, and novel reno-protective treatments targeted to precise AKI phenotypes.    
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Figure legends 
Figure 1 – Platelets and endothelial cells microvesicles increase in AKI patients A – total MV 
concentration and B – MV size distribution in all patients as estimated with NanoSight device. 
Children who developed AKI had higher concentrations of MV of ~130nm in size, in plasma at any of 
the analysed time-points. In infants ~130nm MV increased in concentration after surgery but only in 
patients who did not develop AKI. MV derivation was determined by flow cytometry with specific 
antibodies for C – monocytes (CD14); D – platelets (CD41); E – endothelial cells (CD144). Values in 
line plots represent means of percent of positive particles ±SD for AKI (hatched line) versus no AKI 
(solid line). 
Figure 2 – miRNA in patients with AKI is most different before surgery A – Heatmap of clustered 
means of normalised (quantile) logged concentrations of all analysed miRNA (2CT(cycle threshold)) in all 
patients, children and infants. Clusters of miRNA increase in expression were most evident 6hr after 
surgery. B – Clustering analysis of miRNA expression patterns between age groups and time-points. 
Height in Y-axis indicates Euclidean distance at which the clusters were defined. In All age groups the 
first two clusters were defined at height 37.53, which makes expression miRNA patterns 6 hrs after 
surgery (that separated further at 22.88) clearly different from other patterns that separated at 
25.36. In children two clusters were defined at height 46.45, which further separated at 34.66 and 
25.18 defining two distinct groups of miRNA profiles. In infants, miRNA expression profile before 
surgery (pre) clustered away at height 52.07 making it clearly distinct from other miRNA expression 
patterns that further separated at height 42.53.  
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Figure 2
Table 1 – Baseline characteristics – Continuous data are presented as mean± standard deviation or median and IQR; categorical variables as number 
(percent). CPB, cardiopulmonary bypass. RACHS, Risk Adjusted Congenital Heart Surgery Score. *, constant value in the group 
Variable All age groups (n=24) Children (n=14) Infants (n=5) Newborns (n=5) 
AKI (n=14) 
nonAKI 
(n=10) 
p-
value 
AKI (n=6) 
nonAKI 
(n=8) 
p-
value 
AKI (n=3) 
nonAKI 
(n=2) 
p-
value 
AKI (n=5) 
nonAKI 
(n=0) 
p-
value 
Age (months) 
 
7.85 (0.37-
30.43) 
46.41 (36.37-
90.03) 
0.008 
38.65 (23.57-
169-47) 
58.68 (39.0-
126.75) 
0.529 
5.43 (4.92-
7.85) 
9.35 (8.07-
10.63) 
0.338 9 (0.18-0.43) - - 
             
Height (cm) 
61.0 (53.0-
85.0) 
96.0 (85.0-
122.0) 
0.089 
87.5 (81.0-
149.0) 
105.0 (90.5-
136.5) 
0.740 
56.0 (56.0-
61.0) 
63.0* 0.457 
52.0 (51.5-
53.0) 
- - 
Weight (Kg) 
7.4 (3.65-
11.1) 
14.4 (9.2-
19.1) 
0.036 
11.25 (10.1-
30.5) 
15.45 (13.35-
35.05) 
0.491 
6.8 (5.56-
7.41) 
6.18 (6.15-
6.2) 
0.897 
3.5 (2.98-
3.9) 
- - 
Body Surface Area (m2) 
0.33 (0.22-
0.49) 
0.61 (0.46-
0.82) 
0.022 
0.51 (0.48-
1.16) 
0.67 (0.57-
1.15) 
0.414 
0.3 (0.28-
0.33) 
0.31* 0.881 
0.22 (0.2-
0.23) 
- - 
Sats (%) 
94.0 (91.0-
98.0) 
96.0 (85.0-
99.0) 
0.962 
95.5 (91.0-
99.0) 
97.5 (94.0-
99.5) 
0.862 
98.0 (96.5-
98.0) 
85* 0.007 
91.0 (82.5-
94.0) 
- - 
Cyanotic patients (n,%) 5 (35.7%) 3 (30%) 1.0 1 (16.7%) 1 (12.5%) 1.0 1 (33.3%) 2 (100%) 0.4 3 (60%) - - 
Males (n,%) 7 (50%) 4 (40%) 0.697 2 (33.3%) 3 (37.5%) 1.0 2 (66.7%) 1 (50%) 1.0 3 (60%) - - 
Race   0.930   1.0   NA  - - 
Caucasian (n,%) 11 (78.6%) 8 (80%)  5 (83.3%) 6 (75.0%)  3 (100%) 2 (100%)  3 (60%) - - 
African (n,%) 1 (7.1%) 1 (10%)  0 (0%) 1 (12.5%)  0 (0%) 0 (0%)  1 (20%) - - 
Asian (n,%) 2 (14.3%) 1 (10%)  1 (16.7%) 1 (12.5%)  0 (0%) 0 (0%)  1 (20%) - - 
Table 1
Genetic disease (n,%) 1 (7.1%) 4 (40%) 0.122 1 (16.7%) 4 (50%) 0.301 0 (0%) 0 (0%) NA 0 (0%) - - 
Previous cardiac 
surgery (n,%) 
5 (35.7%) 8 (80%) 0.047 4 (66.7%) 7 (87.5%) 0.301 1 (33.3%) 1 (50%) 1.0 0 (0%) - - 
Preoperative use of 
diuretics (n, %) 
4 (28.6%) 2 (20%) 1.0 1 (16.7%) 1 (12.5%) 1.0 2 (66.7%) 1 (50%) 1.0 1 (20%) - - 
             
Preoperative use of 
prostin (n, %) 
3 (21.4%) 0 (0%) 0.239 0 (0%) 0 (0%) NA 0 (0%) 0 (0%) NA 3 (60%) - - 
Total surgery time 
(min) 
292.5 (226.0-
390.0) 
243.5 (210.0-
263.0) 
0.045 
341.0 (226.0-
415.0) 
243.5 (190.5-
261.0) 
0.114 
335.0 (284.0-
370.5) 
236.5 
(210.0-
263.0) 
0.284 
270.0 
(206.5-
330.0) 
- - 
Total CPB time (min) 
135.5 (114.0-
208.0) 
105.5 (60.0-
127.0) 
0.022 
184.0 (72.0-
275.0) 
105.5 (58.5-
126.0) 
0.113 
135.0 (132.5-
135.0) 
107.5 (65.0-
150.0) 
0.649 
130.0 
(110.0-
181.0) 
- - 
Crossclamp (n, %) 12 (85.7%) 10(100%) 0.493 6 (100%) 8 (100%) NA 3 (100%) 2 (100%) NA 3 (60%) - - 
Crossclamp time (min) 
84.5 (36.0-
137.0) 
53.5 (34.0-
89.0) 
0.493 
88.0 (24.0-
198.0) 
53.5 (34.5-
77.5) 
0.852 
82.0 (60.0-
92.0) 
69.5 (34.0-
105.0) 
0.908 
87.0 (73.0-
109.5) 
- - 
Blood priming (n, %) 14 (100%) 8 (80%) 0.163 6 (100%) 6 (75%) 0.473 3 (100%) 2 (100%) NA 5 (100%) - - 
Ultrafiltration (n, %) 12 (85.7%) 8 (80%) 1.0 4 (66.7%) 6 (75%) 1.0 3 (100%) 2 (100%) NA 5 (100%) - - 
Circulatory arrest (n, %) 2 (14.3%) 1 (10%) 1.0 2 (33.3%) 1 (12.5%) 0.538 0 (0%) 0 (0%) NA 0 (0%) - - 
Return on CPB (n, %) 1 (7.1%) 2 (20%) 0.550 1 (16.7%) 2 (25.0%) 1.0 0 (0%) 0 (0%) NA 0(0%) - - 
 Lowest temperature 
(°C) 
31.25 (25.4-
32.3) 
33.4 (31.8-
35.4) 
0.022 
25.35 (25-
31.5) 
32.0 (31.65-
34.9) 
0.005 
31.0 (29.5-
31.35) 
36.25 (35.9-
36.6) 
0.027 
33.9 (31.2-
35.0) 
- - 
Use of cell saver (n, %) 3 (21.4%) 6 (60%) 0.092 2 (33.3%) 4 (50%) 0.627 0 (0%) 2 (100%) 0.1 1 (20%) - - 
Chest open (n, %) 5 (35.7%) 0 (0%) 0.053 1 (16.7%) 0 (0%) 0.429 0 (0%) 0 (0%) NA 4 (80%) - - 
RACHS-1 2 1  2 1  0 0  0 0  
RACHS-2 4 4  0 2  3 2  1 0  
RACHS-3 4 5  2 5  0 0  2 0  
RACHS-4 3 0  2 0  0 0  1 0  
RACHS-6 1 0  0 0  0 0  1 0  
Table 2 - Perioperative characteristics – Continuous data are presented as mean± standard deviation or median and IQR; categorical variables as number 
(percent). PIM2, Paediatric Index of Mortality 2 Score. PICU, Paediatric Intensive Care Unit. CPAP, Continuous positive airway pressure. RBC, red blood cells. 
*, constant value in the group 
Variable All age groups (n=24) Children (n=14) Infants (n=5) Newborns (n=5) 
AKI (n=14) 
nonAKI 
(n=10) 
p-value AKI (n=6) 
nonAKI 
(n=8) 
p-value AKI (n=3) 
nonAKI 
(n=2) 
p-value AKI (n=5) 
nonAKI 
(n=0) 
p-value 
PIM2 score 
1.95 (1.7-
3.4) 
1.55 (1.4-
1.8) 
0.026 
1.85 (1.7-
2.0) 
1.5 (1.6-
3.35) 
0.029 
2.4 (2.1-
2.9) 
2.0 (1.6-
2.4) 
0.485 2.7 (1-3.6) - - 
PICU admission 
lactates 
(mmol/L) 
3.6 (2.0-
6.4) 
2.05 (1.6-
2.9) 
0.103 4.8 (3.0-9.3) 
2.5 (1.6-
3.35) 
0.181 
2.0 (5.0-
9.0) 
1.25 (1.0-
29.0) 
0.278 5 (2.9-7.8) - - 
Intubation time 
(hours) 
38.75 
(12.7-96) 
4.9 (2.83-
17.25) 
0.026 
10.92 (4.91-
29.9) 
4.92 (2.33-
12.0) 
0.282 
32.0 
(22.38-
38.75) 
265.42 
(2.83-
528.0) 
0.535 
115 (83.8-
271.6) 
- - 
Reintubation (n, 
%) 
2 (14.3%) 1 (10%) 1.0 1 (16.7%) 1 (12.5%) 1.0 1 (33.3%) 0 (0%) 1.0 0 (0%) - - 
Reoperation (n, 
%) 
8 (57.1%) 1 (10%) 0.033 3 (50%) 1 (12.5%) 0.245 1 (33.3%) 0 (0%) 1.0 4 (80%) - - 
12 Hours blood 
loss (ml/kg/hr) 
1.45 ± 
0.59 
0.97 ± 
0,47 
0.045 1.24 ± 0.75 
0.87 ± 
0.47  
0.29 
1.71 ± 
0.41 
1.40 ± 
0.03 
0.334 1.56 ± 0.4 - - 
RBC transfusions 
(ml/kg) 
92.65 ± 
47.98 
29.66 ± 
20.37 
0.001 
53.74 ± 
19.94 
23.05 ± 
16.84 
0.018 
82.01 ± 
19.25 
56.11 ± 
0.21 
0.169 139.5 ± 44.4 - - 
Vasoactive 
Inotrope score 
14.45 
(11.66-
26.5) 
8.55 (3-11) 0.009 
17.13 (10.6-
26.5) 
8.55 (3.0-
10.5) 
0.081 
13.5 (10.5-
21.75) 
10.25 (6.0-
14.5) 
0.518 
14.9 (13.3-
23.7) 
- - 
PICU stay (days) 
5.5 (4.0-
7.0) 
1.0 (1.0-
2.0) 
0.004 4.5 (2.0-7.0) 
1.0 (1.0-
2.0) 
0.043 
5.0 (5.0-
9.0) 
15.0 (1.0-
29.0) 
0.443 6 (4.5-14) - - 
Hospital stay 
(days) 
10.5 (8.0-
22.0) 
6.0 (6.0-
6.0) 
0.03 
9.0 (6.0-
12.0) 
6.0 (5.5-
9.0) 
0.414 
8 (8.0-
15.0) 
6* 0.055 12 (9.5-27) - - 
Cardiac arrest (n, 
%) 
0 (0%) 1 (10%) 0.417 0 (0%) 0 (0%) NA 0 (0%) 1 (50%) 0.4 0 (0%) - - 
Table 2
  
Permanent 
pacemaker (n, 
%) 
1 (7.1%) 1 (10%) 1.0 1 (16.7%) 1 (12.5%) 1.0 0 (0%) 0 (0%) NA 0 (0%) - - 
Use of 
vasodilator (n, 
%) 
5 (35.7%) 1 (10%) 
 
0.341 
1 (16.7%) 0 (0%) 0.429 2 (66.7%) 1 (50%) 1.0 2 (40%) - - 
Mask CPAP (n, 
%) 
3 (21.4%) 0 (0%) 0.239 2 (33.3%) 0 (0%) 0.165 1 (33.3%) 0 (0%) 1.0 0 (0%) - - 
Pleural drainage 
(n, %) 
3 (21.4%) 2 (20%) 1.0 0 (0%) 1 (12.5%) 1.0 2 (66.7%) 1 (50%) 1.0 1 (20%) - - 
Neurological 
event (n, %) 
1 (7.1%) 0 (0%) 1.0 1 (16.7%) 0 (0%) 0.429 0 (0%) 0 (0%) NA 0 (0%) - - 
Phrenic nerve 
palsy (n, %) 
3 (21.4%) 0 (%) 0.239 1 (16.7%) 0 (0%) 0.429 2 (66.7%) 0 (0%) 0.4 0 (0%) - - 
Antibiotics used 
(n, %) 
9 (64.3%) 3 (30%) 0.214 3 (50%) 2 (25%) 0.580 3 (100%) 1 (50%) 0.4 3 (60%) - - 
Table 3 – Differentially expressed miRNAs Difference in miRNA expression levels between patients who developed AKI during cardiac surgery and those 
who did not was analysed using linear regression models with time incorporated as an effect. Whenever the model was statistically significant between AKI 
and non-AKI patients or when the interaction between AKI and time was significant, the difference between AKI and non-AKI groups was further tested 
before and after surgery and Log expression ratio and p-value are reported. Positive expression ratio (log Expr ratio) indicates upregulation in AKI and 
negative expression ratio indicates downregulation. 
 
Age 
group 
Before surgery miRNA family Log Expr 
Ratio 
p-value After surgery miRMA family Log Expr Ratio p-value 
all age 
groups 
hsa-miR-192-5p miR-192-
5p/215-5p 
-0.890 0.040 hsa-miR-10a-
5p 
miR-10-5p -5.190 0.006 
hsa-miR-487a-
3p 
miR-154-
3p/487-3p 
2.450 0.006 hsa-miR-149-
5p 
miR-149-5p no expr. In no-
AKI 
0.006 
hsa-miR-490-3p miR-490-3p 4.660 0.017 hsa-miR-
196b-5p 
miR-196-5p no expr. In no-
AKI 
0.011 
hsa-miR-501-3p miR-501-
3p/502-3p 
 0.480 0.040         
children hsa-let-7g-5p let-7-5p/98-5p -3.267 0.041 hsa-let-7g-5p let-7-5p/98-5p 0.177 0.030 
hsa-miR-152-3p miR-148-
3p/152-3p 
-2.887 0.045 hsa-miR-
125a-3p 
miR-125a-3p 5.924 0.018 
hsa-miR-30b-5p miR-30-5p -2.068 0.025 hsa-miR-
125a-5p 
miR-125-5p 4.886 0.003 
hsa-miR-320a miR-320 1.319 0.028 hsa-miR-223-
3p 
miR-223-3p 1.652 0.026 
hsa-miR-484 miR-484/3155 1.053 0.027 hsa-miR-301-
3p 
miR-130-3p/301-
3p/454-3p 
5.122 0.042 
hsa-miR-885-5p miR-885-5p -1.209 0.046         
infants hsa-let-7g-5p let-7-5p/98-5p 18.559 0.007 hsa-let-7g-5p let-7-5p/98-5p 1.248 0.044 
hsa-miR-125b-
5p 
miR-125-5p 19.916 0.001 hsa-miR-103-
3p 
miR-103-3p/107 1.957 0.018 
hsa-miR-133a-
3p 
miR-133a-
3p.2/133b 
18.398 0.007 hsa-miR-15a-
5p 
miR-15-5p/16-
5p/195-5p/424-
5p/497-5p 
1.018 0.038 
Table 3
hsa-miR-150-5p miR-150-5p -1.172 0.013 hsa-miR-
193a-5p 
miR-193a-5p 3.979 0.015 
hsa-miR-152-3p miR-148-
3p/152-3p 
17.618 0.001 hsa-miR-511-
5p 
miR-511-5p 4.827 0.003 
hsa-miR-193a-
5p 
miR-193a-5p 17.515 0.001 hsa-miR-652-
3p 
miR-652-3p no expr. In no-
AKI 
0.028 
hsa-miR-27b-3p miR-27-3p 18.184 0.001 hsa-miR-888-
5p 
miR-885-5p 6.600 0.019 
hsa-miR-320a miR-320 -1.012 0.039         
 
Table 4 – Pathway analysis summary as determined by the Qiagen Ingenuity software. Canonical pathways are variety of signalling or metabolic pathways 
available in the Ingenuity database. Renal pathways indicate nephrotoxic effect of certain molecules as listed in the Ingenuity database. Significance level 
(p-value) is calculated by Fisher's exact test and indicates the probability of association of molecules regulated by the identified miRNAs with above 
mentioned pathways by random chance alone. Pathway overlap indicates overlap of the identified miRNA-regulated molecules with the Ingenuity database. 
Target genes show genes affected by the identified miRNAs also present among the pathway’s molecules. Bold target genes indicate experimentally verified 
miRNA targets.  
Time 
point 
Age 
group 
Pathway p-value Pathway 
overlap 
Target genes 
B
ef
o
re
 s
u
rg
er
y 
All age 
groups 
Canonical 2-amino-3-carboxymuconate Semialdehyde 
Degradation to Glutaryl-CoA 
1.28E-02 10.00% ACMSD 
dTMP De Novo Biosynthesis 1.79E-02 7.10% DHFR 
Mitochondrial Dysfunction 2.43E-02 1.10% PRDX3, VDAC1 
NAD Phosphorylation and 
Dephosphorylation 
2.55E-02 5.00% ACPP 
mTOR Signaling 2.86E-02 1.00% EIF3M, RICTOR 
Renal Renal Inflammation 1.79E-02 - 
1.79E-02 
 DHFR 
Renal Nephritis 1.79E-02 - 
1.79E-02 
 DHFR 
Renal Necrosis/Cell Death 1.10E-01 - 
5.92E-02 
 PRDX3, VDAC1 
Renal Proliferation 2.47E-01 - 
2.47E-01 
  VDAC1 
Children Canonical Cytotoxic T Lymphocyte-mediated Apoptosis 
of Target Cells  
6.39E-05 12.50% CASP2*, HLA-A, HLA-B, HLA-C 
Neuroprotective Role of THOP1 in 
Alzheimer's Disease  
2.69E-04 8.70% PRKAR2A, HLA-A, HLA-B, HLA-C 
Colorectal Cancer Metastasis Signaling  3.41E-04 3.20% ADCY10, CASP3, HNF1A, MMP10, 
PRKAR2A, PTGER3, PTGER4, TGFBR1,  
Factors Promoting Cardiogenesis in 
Vertebrates  
4.17E-04 5.40% HNF1A, NOG, PRKCZ, TGFBR1, TGFBR3 
Table 4
Th2 Pathway  5.75E-04 4.00%  HLA-A, HLA-B, MAF, SOCS3, TGFBR1, 
TGFBR3 
Renal Glomerular Injury  3.27E-01 - 
4.54E-04  
 LAMB2, CHRNA7, CASP3, HNF1A, MAFB, 
DICER1 
Renal Proliferation  3.93E-03 - 
3.93E-03  
 ATG5, BICC1, FGF1, PRKCZ, PTGER3, 
SOCS3 
Nephrosis  6.80E-03 - 
6.80E-03  
 LAMB2 
Renal Dysfunction  6.80E-03 - 
6.80E-03  
 HNF1A 
Renal Dysplasia  2.03E-02 - 
8.06E-03  
  BICC1, ITGA8 
Infants Canonical Factors Promoting Cardiogenesis in 
Vertebrates 
3.28E-05 7.60% NOG, PRKCZ, SMAD4, SMAD5, SMAD9, 
TGFBR1, TGFBR3 
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 
1.52E-04 4.50% APOC4, ARG2, MAP3K11, MAP3K13, 
PPP1R7, PPP2CA, PPP2CB, PRKCZ, SAA4 
PTEN Signaling 1.86E-04 5.80% APOC4, ARG2, MAP3K11, MAP3K13, 
PPP1R7, PPP2CA, PPP2CB, PRKCZ, SAA4 
HIPPO signaling 2.09E-04 6.90% PPP1R7, PPP2CA, PPP2CB, PRKCZ, 
SMAD4, SMAD5 
Cytotoxic T Lymphocyte-mediated Apoptosis 
of Target Cells 
2.54E-04 12.50% CASP2*, HLA-A, HLA-B, HLA-C 
Renal Renal Necrosis/Cell Death  2.47E-01 - 
9.46E-05 
 ADORA1, BAX, BCL2L11, CASP3, DUSP, 
F2, FGF1, GRB10, IGF1R, MAFB, PMAIP1, 
RFXANK, SGPL1, TNFSF10, VEGFA, 
KIRREL, PTH1R 
Glomerular Injury  3.37E-01 - 
2.81E-04 
 FOXC2, VEGFA, KIRREL, LAMB2, MAFB, 
BCL2L11, CHRNA7, CASP3, DUSP1, 
DICER1, SMAD4 
Nephrosis  9.83E-02 - 
9.74E-03 
 LAMB2, ADORA1, PDE7B 
Renal Inflammation  4.78E-02 - 
9.74E-03 
 ADORA1,BAX,BCL2L11,LAMB2,PDE7B,PI
GR,PPP2CA,SMAD4,VEGFA 
Renal Nephritis  4.78E-02 - 
9.74E-03 
  ADORA1,BAX,BCL2L11,LAMB2,PDE7B,PI
GR,PPP2CA,SMAD4,VEGFA 
A
ft
e
r 
su
rg
er
y 
All age 
groups 
Canonical PTEN Signaling 2.34E-02 1.70% BCL2L11, PDGFRB 
Arginine Degradation I (Arginase Pathway) 2.51E-02 7.70% ARG2 
Arginine Degradation VI (Arginase 2 
Pathway) 
3.09E-02 6.20% ARG2 
Urea Cycle 3.84E-02 5.00% ARG2 
Citrulline Biosynthesis 4.97E-02 3.80% ARG2 
Renal Glomerular Injury  2.87E-01 - 
5.86E-03 
 BCL2L11, PDGFRB 
Renal Necrosis/Cell Death  1.85E-01 - 
8.60E-03 
 AMER1, BCL2L11, STRA6, TMX1, PTGR1 
Renal Proliferation  9.34E-02 - 
9.34E-02 
 PDGFRB 
Renal Inflammation  1.27E-01 - 
1.27E-01 
 BCL2L11 
Renal Nephritis  1.27E-01 - 
1.27E-01 
  BCL2L11 
Children Canonical Dopamine Receptor Signaling 5.45E-04 5.50% PPP1R7, PRKAR2A, PRL, PTH, PTS 
Antiproliferative Role of TOB in T Cell 
Signaling 
8.75E-04 11.50% CDC34, SMAD4, TGFBR1 
PTEN Signaling 1.95E-03 4.10% CASP3, CSNK2A1, IGF1R, TGFBR1, 
TGFBR3 
STAT3 Pathway 2.11E-03 5.40%  IGF1R, MAP3K11, TGFBR1, TGFBR3 
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 
3.46E-03 3.00% APOC4, ARG2, MAP3K11, MAP3K13, 
PPP1R7, SAA4 
Renal Renal Atrophy  7.74E-02 - 
2.58E-05 
 ADAMTS1,LRRK2,OVOL1,PTH,SLC4A1 
Renal Necrosis/Cell Death  4.83E-01 - 
3.18E-03 
 ALDH3B1,CASP3,F2,GRB10,IGF1R,MAFB,
PSIP1,RFXANK,SGPL1,TNFSF10, LRRK2 
Renal Inflammation  3.89E-01 - 
7.29E-03 
 LRRK2,PIGR,SLC19A3,SMAD4 
Renal Nephritis  3.89E-01 - 
7.29E-03 
 LRRK2,PIGR,SLC19A3,SMAD4 
Glomerular Injury  3.58E-01 - 
1.45E-02 
  CHRNA7, DICER1, SMAD4, MAFB, CASP3 
Infants Canonical PTEN Signaling 5.52E-07 7.40% BCL2, BCL2L11, CASP3, FGFR1, IGF1R, 
MAPK3, RAF1, TGFBR1, TGFBR3 
STAT3 Pathway 2.07E-06 9.50% BCL2, FGFR1, IGF1R, MAP3K11, RAF1, 
TGFBR1, TGFBR3 
Ovarian Cancer Signaling 2.28E-05 5.50% BCL2, FGFR1, MAPK3, PRKAR2A, RAF1, 
VEGFA, WNT16, WNT2B 
Apoptosis Signaling 7.87E-05 6.70% AIFM1, BCL2, BCL2L11, CASP3, MAPK3, 
RAF1 
Melanocyte Development and Pigmentation 
Signaling 
1.27E-04 6.20% BCL2, FGFR1, MAPK3, PRKAR2A, RAF1, 
RPS6KA3 
Renal Glomerular Injury  3.76E-01 - 
5.11E-06 
 ARHGDIA,BCL2,CHRNA7,UMOD,VEGFA,
WT1,CHRNA7,DICER1,FGF2,CDKN1C, 
CASP1 
Renal Necrosis/Cell Death  1.88E-01 - 
5.05E-04 
 AMER1,BCL2,BCL2L11,CASP3,F2,FGF2,G
RB10,IGF1R,RAF1,TNFSF10,UMOD,VEGF
A,WT1 
Renal Inflammation  2.56E-01 - 
6.20E-04 
 ARHGDIA,BCL2,BCL2L11,,TNFSF13B,UM
OD,VEGFA,WT1 
Renal Nephritis  2.56E-01 - 
6.20E-04 
 ARHGDIA,BCL2,BCL2L11,,TNFSF13B,UM
OD,VEGFA,WT1 
Renal Damage  1.41E-01 - 
1.13E-03 
  ARHGDIA, CHRNA7, DICER1, FGF2 
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Methods  
Study population 
Study population included 24 consecutive patients who underwent surgery for congenital heart 
diseases at the East Midlands Congenital Heart Centre (Glenfield Hospital, Leicester, UK) between 
October 2014 and February 2015. Participants were prospectively recruited for this observational 
feasibility study if they were younger than 18 years old, their body weight was greater than 2 kg and 
their operation required cardiopulmonary bypass (CPB). Patients were excluded if they had a 
diagnosed pre-existing inflammatory state such as sepsis undergoing treatment or a chronic 
inflammatory disease and a diagnosis of acute kidney injury within 5 days before surgery. Emergency 
or salvage procedures were excluded, as well as patients supported by Extracorporeal Membrane 
Oxygenation (ECMO) or likely to require postoperative ECMO. Previous nephrotoxin use such as 
contrast solutions was not an exclusion factor as long as the serum creatinine (SCr) values were 
within reference range at the time of surgery. The study was approved by The East Midlands – 
Nottingham 1 Research Ethics Committee. Written informed consent from parents or legal guardians 
was obtained before enrolment and was confirmed before every invasive procedure when possible. 
Written informed assent was collected for patients aged 11 to 15 years where appropriate. 
Competent patients aged 16 or 17 provided their own consent. 
Patients were defined as newborns if 30 days old or younger, infants if aged between 30 days and 12 
months and children if older than 12 months.  
All eligible patients received the standard preoperative care, as determined by the attending 
physician. All patients underwent surgery through a median sternotomy and the use of 
extracorporeal circulation. Anaesthesia was standardized where possible and was induced by 
servoflurane or isoflurane, along with the administration of neuromuscular blockade (rocuronium or 
Supplemental Materials and Methods
atracurium) and analgesia using fentanyl and/or morphine. Patients for whom servoflurane was 
unsuitable were given an intravenous induction using ketamine, propofol or midazolam. The 
cardiopulmonary bypass (CPB) was conducted with a non-heparin coated ‘semi-closed circuit’ 
(Maquet-Jostra, Hirrlingen, Germany) with a soft shell venous reservoir, a roller pump (Stockert, 
Munchen Germany), a microporous hollow fibre oxygenator (Quadrox, Maquet-Jostra, Hirrlingen, 
Germany) and a 40 micron arterial filter. The circuit was primed with a combination of the 10% 
mannitol, 8.4% sodium bicarbonate, plasmalyte pH 7.4, and succelylinated volplex. Temperature 
during CPB was managed after discussion with the surgical team and according to the operative 
technique. A red cell blood prime was used to maintain a haematocrit of > 30 g/L according to 
patient characteristics. All patients were admitted to the paediatric intensive care unit (PICU) 
following surgery. The use of inotropes, vasopressors or diuretics was at the discretion of the 
attending physician. 
Feasibility outcomes 
Recruitment and dropout rates were monitored. Protocol adherence was evaluated through the 
monitoring of protocol violations defined as any change, deviation, or departure from the study 
design or procedures of research project that was not approved prior to study initiation or 
implementation.  Major violations were considered in case of a serious and/or continuous failure to 
comply with the protocol, standard operating procedures, good clinical practice (GCP) or trial 
regulations, if there was a significant negative impact to subject safety or if there was a significant 
damage to the completeness, accuracy and reliability of the data collected for the study. Minor 
protocol violations were considered if the previous definition was not applicable and included the 
failure to obtain specified clinical data, blood volume or urine samples required for analysis at the 
required time (deviation of more than 60 mins from the planned collection time). For an individual 
participant, the end of the trial was defined as 7 days after the index surgical procedure or as 
hospital discharge if earlier. Laboratory protocol non-adherence was defined as the failure to 
complete laboratory essays following the study protocol.  
Definition of AKI and clinical outcomes 
The reference standard to classify AKI was defined according to the Kidney Disease: Improving 
Global Outcomes (KDIGO) criteria 1 as an increase in SCr by ≥ 0.3 mg/dl (≥ 26.5 µmol/l) or an increase 
in SCr to ≥ 1.5 times baseline, or a urine volume  < 0.5 ml/kg/h for 6 hours. AKI was also staged 
according to the KDIGO guidelines. The time frame for the assessment of AKI was up to 7 days or 
hospital discharge if earlier. Urine output was routinely monitored until the end of the follow up 
period. Despite the uncertainty in defining AKI in neonates 2, KDIGO criteria were applied to the 
whole population in the absence of specific criteria for new-borns in guidelines. In addition, to 
reflect the fact that young infants may be unable to generate high serum creatinine values we also 
used estimated creatinine clearance was used to define Stage 3 AKI, using the Schwartz equation,3 as 
per the pRIFLE criteria. 
Preoperative data likely to influence the post-operative recovery and operative data such as 
procedure details, bypass time and cross clamp time were recorded in a prospective ad hoc 
database. Risk adjustment for congenital heart surgery (RACHS-1) category was assigned to each 
surgical procedure performed 4. Postoperative morbidity and mortality, duration of mechanical 
ventilation, ICU and hospital stay and other non-biochemical outcomes were collected up to seven 
days after surgery or discharge if earlier. The Pediatric Multiple Organ Dysfunction Score (P-MODS) 5 
and the Vasoactive-Inotropic Score (VIS) 6 were monitored during PICU stay. Post-operative gas 
analysis and routine blood results were carried out according to the attending physician’s decision 
and were recorded until seven days after surgery or discharge if earlier.  
Biochemical markers 
Serum and urine concentrations of creatinine (UCr and SCr, respectively) were determined using 
creatinine assay kit (Abcam, Cambridge UK) as recommended by the manufacturer Concentration of 
troponin cTnI was estimated in serum using a commercial kit from Enzo Life sciences (Lausanne, 
Switzerland). Urine neutrophil gelatinase-associated lipocalin (NGAL) was measured in urine using 
ELISA kit (EKF Diagnostics, Cardiff UK).  
Concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis factor α (TNFα), 
monocyte chemoattractant protein 1 (MCP-1), monocyte chemoattractant protein 3 (MCP-3) and 
macrophage inflammatory protein 1 (MIP-1), as well as markers of endothelial injury such as 
circulating intercellular adhesion molecule (ICAM) and E-selectin were simultaneously quantified in 
plasma using the ProcartaPlex™ immunoassay kits (eBioscience, San Diego, CA, USA) and measured 
with the MagPix multiplex array system employing Luminex xMAP technology in combination with 
the xPonent Software (Luminex corporation, Austin Texas US). 
Haemoglobin concentration was calculated as previously described 7. Briefly, the samples were spun 
at 1,800 xg for 15 min and the resulting supernatant was further spun for 5 min at 20,000 xg. The 
supernatant was diluted 5x with PBS and absorbance measured at 415nm, 450nm and 700nm using 
Multiplate reader Enspire (PerkinElmer). Haemoglobin concentration was calculated as follows: Hb = 
1.58xA415 - 0.95xA450 - 2.91xA700. 
Platelet and leukocyte activation was estimated by flow cytometry (Cyan ADP, Beckman Coulter, 
Brea, CA) in citrated patients’ blood samples. For platelets samples were labelled with FITC-coupled 
CD62E (Abcam, Cambridge, UK), and PE-coupled CD41, Affymetrix, Santa Clara, CA, USA). For 
leucocyte FITC-labelled CD64 and PE-labelled CD163 (Affymetrix) were used and red cells were lysed 
using FACSlyse solution from BD Biosciences.  
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Supplemental Figure legend 
Supplemental Figure 1 – Study design and kidney function A – STROBE diagram, B – Serum 
creatinine. Values in line plots represent means ±SD. 
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